Co-chaired by Aetna's Michael Kolodziej, the 2016 conference was seen as the most targeted and high-level gathering on commercialization of cancer products in the US.
Join 150+ senior executives attended, including the following leading oncology innovators: Celgene;Eisai; Janssen; Novartis; BMS; Lilly; Genentech; Baxalta; GSK and Takeda.
Here's why you should attend:
Value-Based Pricing Metrics Round Robin - Hear why payers are hungry for these models, how they may leverage them, and which metrics will make a significant impact on the market access environment
Determine How to Best Position Your Brand in an Evolving Market - Work cross-functionally with teams to address the challenges these metrics bring to develop a stronger market access trajectory by better demonstrating your products' importance.
Prepare for Stakeholder's Demands - Adopt new business strategies that effectively generate, manage, and apply relevant health economic and clinical data from drug development through reimbursement
Set Your Brand Apart in the Changing Payment Model Landscape - Decipher how potential APMs may impact your products and determine which are likely to have significant risks for the adoption of innovative drugs and biologics
Silver pass: USD 2000
Speakers: Celgene, takeda, Janssen, BMS, Novartis, GSK, ASCO, ICER, Aetna, genentech, Baxalta, QuintilesIMS,
Sign in to add slides, notes or videos to this session